SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Pfizer Inc.'s Vyndaqel(R) (tafamidis) First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)